Börse 5 Januar 2026 - 3 Februar 2026

March 12, 2026, 2:24 AM EDT. Medline's (MDLN) shares fell roughly 10.5% over 30 days, trading around $42.39, despite a 4.4% year-to-date gain. The stock commands a price-to-earnings (P/E) ratio of 29.7x, above the US Medical Equipment industry's 27.2x and peer average of 26.5x, indicating a market premium. Analysts forecast earnings growth of 16.54% annually and revenue growth of 7.1%, with price targets about 25.5% higher than current levels. However, Medline's lower net profit margin of 4.1% (down from 4.7%), a modest 6% return on equity (ROE), and interest expenses not fully covered by earnings raise valuation concerns. The recent share pullback and fundamental challenges may temper investor expectations despite optimistic growth forecasts and earnings quality considerations.